Agilent Technologies, Inc.

Agilent Technologies, Inc. Earnings Recaps

A Health Care 3 recaps
Next earnings: August 26, 2026 (estimated) · full calendar
Q2 2026 May 29, 2026

Shares rose 17.6% on strong revenue growth, margin expansion, and double-digit EPS growth that materially beat expectations, driven by broad-based strength across end markets and continued replacement cycle momentum.

Key takeaways
  • Reported $1.83 billion in revenue, up 6.3% core year-over-year, exceeding the high end of guidance by 80 basis points.
  • Operating margin expanded 130 basis points year-over-year to 26.4%, surpassing guidance despite challenging macro and geopolitical conditions.
  • EPS of $1.49 grew 14% year-over-year and topped guidance by $0.07.
  • Balanced growth across key segments: Pharma +6%, Chemical & Advanced Materials +8%, Diagnostics & Clinical +11%, and Forensics over +50%, supported by significant new contracts and market share gains.
  • Instrument revenue saw high single-digit growth with strong replacement cycle momentum and book-to-bill above 1 for the ninth consecutive quarter.
Full recap
Q1 2026 Feb 27, 2026

Agilent Technologies posted solid first-quarter results for fiscal 2026, with revenues of $1.8 billion, reflecting a 4.4% core growth despite weather-related disruptions, while operating margins held steady at 24.6%.

Key takeaways
  • Revenue growth was slightly impacted by a $10 million loss from a U.S. winter storm but was otherwise within November guidance range.
  • Operating margins remained stable at 24.6%, with expectations for sequential improvement driven by increasing volumes and decreasing tariff headwinds.
  • EPS for the quarter was reported at $1.36, with adjusted figures suggesting stronger performance above guidance midpoints.
  • Agilent's enterprise services business continues to grow rapidly, marking a low double-digit CAGR and enhancing customer relationships with major biopharma accounts.
  • New product introductions, particularly the Altura column portfolio and Pro iQ LC/MS, have shown strong market reception, indicating robust demand and competitive advantage in the biopharma space.
Full recap
Q4 2025 Nov 25, 2025

Agilent Technologies delivered a robust fourth quarter in fiscal 2025, with revenue rising 7.2% year-over-year to $1.86 billion, marking the sixth consecutive quarter of core growth acceleration and exceeding guidance.

Key takeaways
  • Earnings per share reached $1.59, surpassing the midpoint of guidance.
  • Strong demand in liquid chromatography (LC) and liquid chromatography-mass spectrometry (LCMS) contributed to broad-based momentum across the portfolio.
  • The Ignite operating system drove over 200 basis points of sequential margin improvement.
  • Innovative product launches, such as the Infinity 3 and Pro IQ LCMS, yielded significant customer engagement and sales growth.
  • Agilent's focus on artificial intelligence is enhancing operational efficiency and accelerating innovation across its product lines.
Full recap